Optimizing therapy in previously treated non-small cell lung cancer.

Area of Science:

• Oncology
• Pharmacology
• Clinical Trials

Background:

• Recent advancements have identified novel cytotoxic agents and targeted therapies for non-small cell lung cancer (NSCLC).
• These therapies are being investigated in various stages of NSCLC, including loco-regional and advanced disease.
• Focus is on agents with single-agent activity or those enhancing chemotherapy efficacy.

Purpose of the Study:

• To review Phase III trial results of cytotoxic agents and tyrosine kinase inhibitors in previously treated advanced NSCLC.
• To identify predictors of favorable outcomes in patients receiving these novel therapies.
• To propose a rational approach for therapeutic selection and discuss future strategies.

Main Methods:

• Review of Phase III clinical trial data for specific cytotoxic agents (docetaxel, pemetrexed, topotecan) and epidermal growth factor receptor tyrosine kinase inhibitors (erlotinib, gefitinib).
• Analysis of studies involving previously treated patients with advanced NSCLC.
• Examination of treatment outcomes and patient characteristics.

Main Results:

• Several cytotoxic and targeted agents have been evaluated in Phase III trials for previously treated advanced NSCLC.
• Data from trials involving docetaxel, pemetrexed, topotecan, erlotinib, and gefitinib are summarized.
• The review focuses on identifying factors associated with positive treatment responses.

Conclusions:

• Understanding predictors of favorable outcomes is crucial for selecting appropriate therapies in advanced NSCLC.
• Ongoing pivotal trials and future strategies aim to optimize treatment selection and improve patient outcomes.
• A rational approach to therapeutic selection is needed for this patient population.